文献速递白血病

急性早幼粒细胞白血病患者中砷诱导的神经毒性

Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
PubMed 文献 · Br J Haematol · 2024-01-10

这项在澳大利亚23个中心开展的回顾性研究纳入2008至2023年接受含砷治疗的487例急性早幼粒细胞白血病(APL)患者,任何级别神经毒性发生率为23%,以周围神经病为主(91%),且随BMI升高而增加(非肥胖16%、肥胖I级25%、肥胖II-III级41%,p<0.001);多因素分析中肥胖II-III级和诱导累积剂量>500 mg仍与神经毒性显著相关,作者认为肥胖患者接受高剂量砷时应考虑预防性减量。

要点

  • 任何级别神经毒性发生于113例(23%)患者,其中周围神经病占91%。
  • 神经毒性发生率随BMI升高:非肥胖16%、肥胖I级25%、肥胖II-III级41%(p<0.001)。
  • 多因素分析中肥胖II-III级与诱导剂量>500 mg仍与神经毒性显著相关。

核心结论

  • 研究强调BMI与三氧化二砷剂量和神经毒性之间存在强关联。
  • 作者认为肥胖患者接受高剂量砷时应考虑预防性减量。

研究设计与样本

  • 大型多中心回顾性研究,纳入2008至2023年澳大利亚23个中心接受含砷治疗的487例急性早幼粒细胞白血病(APL)患者。
  • 主要结局为神经毒性发生率,次要结局包括神经毒性与肥胖及累积砷剂量的关系。

主要发现

  • 任何级别神经毒性发生于113例(23%)患者,以周围神经病为主(91%)。
  • 多数事件为1-2级(85%),3级占12%,4-5级占3%。
  • 神经毒性发生率随BMI升高:非肥胖16%、肥胖I级25%、肥胖II-III级41%(p<0.001)。
  • 单因素分析中肥胖I级(OR 1.81,p=0.036)、肥胖II-III级(OR 3.93,p<0.001)、体重>100 kg(OR 2.72,p<0.001)、每日三氧化二砷剂量>15 mg(OR 5.05,p<0.001)及诱导累积剂量>500 mg(OR 3.95,p<0.001)均与神经毒性显著相关。
  • 多因素分析中肥胖II-III级和诱导剂量>500 mg仍显著。

临床怎么用

  • 作者认为肥胖患者接受高剂量砷时应考虑预防性减量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arsenic trioxide is an essential component of therapy for acute promyelocytic leukaemia (APL) and is currently dosed on actual body weight with no upper limit. Arsenic-induced neurotoxicity is a well-recognised complication; however, there is uncertainty about its relationship to arsenic dose and obesity. We conducted a large multicentre retrospective study of 487 patients with APL treated with arsenic-based therapy across 23 sites in Australia from 2008 to 2023. The primary outcome was incidence of neurotoxicity, and secondary outcomes included relationship of neurotoxicity to obesity and cumulative arsenic dose. Any-grade neurotoxicity occurred in 113 (23%) patients, predominantly peripheral neuropathy (91%). Most events were grade 1-2 severity (85%), with grade 3 events in 12% and grade 4-5 in 3%. The incidence of neurotoxicity increased with BMI (non-obese: 16%, obesity class I: 25%, obesity class II-III: 41%; p < 0.001). On univariable analysis, obesity class I (OR 1.81, p = 0.036), obesity class II-III (OR 3.93, p < 0.001), weight >100 kg (OR 2.72, p < 0.001), daily arsenic trioxide dose >15 mg (OR 5.05, p < 0.001) and cumulative induction dose >500 mg (OR 3.95, p < 0.001) were all significantly associated with neurotoxicity. Obesity class II-III and induction dose >500 mg remained significant on multivariable analysis. Our study highlights the strong association between BMI, arsenic trioxide dose and neurotoxicity. Pre-emptive dose reductions should be considered for obese patients receiving high doses of arsenic.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Loh Z, Ashby M, Van Veldhuizen E, et al. Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia. Br J Haematol. 2024. PMID: 38198799. doi:10.1111/bjh.19297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。